

Use of mechanistic information to evaluate the hazard and predict health effects of replacement flame retardants.

Lola Bajard, Ludek Blaha, Lisa Melymuk

*Research Centre for Toxic Compounds in the Environment (RECETOX), Masaryk University,
Brno, Czech Republic*


CHE Webinar, June 20



MUNI | RECETOX

Flame retardants (FRs)

- Added to materials to delay flammability.
- Broadly detected, particularly in dusts and also in human matrices
- People presumably chronically exposed



<https://www.ewg.org/enviroblog/2016/08/flame-retardants-why-they-re-our-homes-and-how-avoid-them>

Replacement FRs

Since the years 2000, the long used PBDEs and HBCDD have been restricted, and **100s of diverse chemicals are used as replacement**



62 FRs preselected by experts from HBM4EU* - we focus on **replacement (non restricted) : 52 FRs**



evaluate their hazard, identify their mechanisms of toxicity.

*hbm4eu scoping document - <https://www.hbm4eu.eu/mdocs-posts/scoping-documents-for-2018/>

PBDEs: Polybrominated diphenyl ethers; HBCDD: hexabromocyclododecane



Importance of mechanistic information

- ➔ 62 FRs preselected by experts from HBM4EU* - we focus on **replacement (non restricted) : 52 FRs**
- ➔ evaluate their hazard, **identify their mechanisms of toxicity.**

- To predict their impact on health
- To provide a mechanism for health effects
- To identify biomarkers of effects

Procedure – Collecting toxicological data

Non restricted/replacement only – 52 FRs

Systematic search for *in vivo** toxicological studies (open literature and reports from agencies)

results from *in vitro* tests of ToxCast

* Animal studies and human epidemiology studies

The US-EPA ToxCast programs and dashboard

- Part of the shift in toxicity testing toward alternative to animal studies
- ToxCast and Tox21 programs use high throughput methods to test thousands of chemicals over a large spectrum of *in vitro* assays (e.g., in cells).
- Open and easy access to the results through the dashboard for 9076 chemicals in 1192 Assays - <https://actor.epa.gov/dashboard/>



Data collected from the ToxCast dashboard

The screenshot displays the EPA iCSS ToxCast Dashboard interface. On the left, the 'Assays - 883' filter is highlighted with a red circle. Below it, the 'Actives - MC Only' checkbox is also highlighted with a red circle. The main panel shows the 'Bioactivity' tab with a 'Tested Samples - Multiple Concentrations' table. The table has columns for Assay Name, Assay Endpoint Name, Hit Call, Plot (Win), Full PI, Model, AC50, and Conc U. The first row is highlighted, showing 'ATG_PXR_TRANS_up' as the Assay Name, 'ACTIVE' as the Hit Call, and '0.358' as the AC50 value, both of which are circled in red. Below the table, two callout boxes provide instructions: one pointing to the 'Actives - MC Only' filter and another pointing to the 'AC50' column.

Choose a view: Assays Database: prod_dashboard_v2
 Chemicals Dashboard: v2

Chemicals - 1 Assays - 883

13674- Chemical Name.. Assay Endpoint Name.. Gene Symbc

CASRN Chemical Actives - MC Only All Tested

13674-87-8 TDCPP Assay Component Endpoint Name

Start Tutorial - Bioactivity Tab

Tested Samples - Multiple Concentrations


Actives Only Representative Samples Only Download Clear Samples

Assay Name	Assay Endpoint Name	Hit Call	Plot (Win)	Full PI	Model	AC50	Conc U
ATG_PXR_TRANS_up		ACTIVE			Gain-Loss	0.358	uM

➤ % of assays in which the FR is active


➤ Select low AC50 (potential molecular target)

Procedure – toxicological data availability



* Animal studies and human epidemiology studies

Procedure – evaluation of hazard



* Animal studies and human epidemiology studies

Focus on 9 FRs – need to identify their mechanisms of toxicity

Substantial information and
toxicological concern

9 FRs


- Insufficient to clearly associate health effects to exposure (e.g., lack of human studies)
- **No mechanism of toxicity** clearly identified

 Use the AOPwiki

The AOPwiki




- Online knowledge base supported by several international authorities
- Open access to all existing AOPs, MIEs, KEs, AOs
- Each AOPs, MIEs, KEs, AOs has its own page



Evidence from Literature (original papers, reports) and ToxCast on
TBBPA, TDCIPP, TPhP, TMPP, TNBP, TBOEP, EHDP, TCIPP and TCEP

How to merge information from literature and information from the AOPwiki?



Adverse Outcome Pathway (AOP)

Linking information from literature to existing AOPs


Step 1: **Identify individual biological effects** of the chemical and collect evidences from the literature
„Re-structure“ the complex info from the literature into „individual“ biological effects

Step 2: **Link biological effects to existing Key Events (KE) and AOPs to which they belong** from the AOPwiki


*Tricky part - variable/different terminology used in literature vs. Terminology in AOPwiki
> redundancy, > information can get lost*

Step 3: **Select AOPs for which we found evidence linking the chemical to at least 3 KEs**, with strong evidence for at least 1 KE, and of good enough quality

Step 1: Identify individual biological effects




Step 2: Link biological effects to existing Key Events (KE) using AOPwiki




The screenshot shows the AOPwiki interface. The 'Key Events' tab is selected and highlighted with a red box. A search input field contains the text 'teratogenicity', also highlighted with a red box. Below the search field, a message states 'No title search results matched your request'. Underneath, the 'Key Events Fulltext Search Results' section displays a table with two rows. The second row, with ID 1001 and title 'Increased, Developmental Defects', is highlighted with a red box. A red arrow points from the search input field to this highlighted row.

Id	Title ▲	Short name	Biological organization
1505	cell cycle disorder	cell cycle disorder	Cellular
1001	Increased, Developmental Defects	Increased, Developmental Defects	Molecular

Step 3: Select “plausible AOPs” (chemical linked to 3 or more KEs)




Step 3: Select “plausible AOPs” (chemical linked to 3 or more KEs)



Most relevant AOs and corresponding plausible AOPs for Cat I FRs

Figure 2: Illustration of major results from literature/ToxCast/AOP search for Category I FRs

Major AOs are indicated (in ovals) with corresponding plausible AOPs (arrows with their number from the AOP-wiki) and MIE (in hexagons). A color code indicates for which Cat I FR the AOP is a plausible mechanism, or the AO or MIE has been reported. No colors at MIE indicate that the effects of FRs have not been reported so far or AC50 from ToxCast was above 1µM. Several other AOs, AOPs and MIEs not illustrated in this figure have been investigated and are listed in Supplementary Table S3. (Disclaimer: because of dynamic nature of AOP-Wiki, the information on AOPs presented in the paper reflects state of the art as of June 2018, when the information from AOP-Wiki was collected).



<https://rdcu.be/boCGI>


Most relevant AOs and corresponding plausible AOPs for Cat I FRs

Figure 2: Illustration of major results from literature/ToxCast/AOP search for Category I FRs

M
C
i
ren.
when the information from AOP-Wiki was collected).



- Identify mechanisms underlying health effects reported in only few studies: neurotoxicity, hepatotoxicity and decrease in male fertility.
- Identify gaps in mechanistic knowledge (e.g., lack of molecular targets)
- Predict potential impacts on human health that did not receive much attention (e.g., metabolic disorders or breast cancer)



<https://rdcu.be/boCGI>



Conclusions

For replacement chemicals with rather little toxicological data available:

- Information from ToxCast can be a useful to predict toxicological concern (e.g. PBP).

However, no/low activity in ToxCast assays does not necessary imply low toxicological concern in vivo.

- AOP wiki is useful to make optimum use of the data available to identify mechanisms, predict potential impacts on human health and identify gaps in mechanistic knowledge

However it still has limitations, e.g. incomplete representativity of the biological processes

Acknowledgments



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 733032 HBM4EU, the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 734522, and the Czech Ministry of Education, Youth and Sport (LO1214).

Thanks to HBM4EU project team for initial structure of compound categorization.

MUNI | RECETOX



Lisa Melymuk
Ludek Blaha

Thank you for your attention!

